Jubilant Life Sciences Shares Jump Five Percent on Gilead Pact for Covid-19 Therapy Drug
The Gilead pact signed between Jubilant Life Sciences' subsidiary Jubilant Generics Ltd and Gilead, will grant the former the right to register, manufacture and sell the latter's investigation drug, remdesivir - a potential therapy for Covid-19.